

UNDERSTANDING THE VETERINARY THERAPEUTICS APPROVAL PROCESS

Author
Nihar R Pandey, PHD
Chief Scientific Officer
Paws Pharmaceuticals

GET IN TOUCH WITH THE PAWS TEAM



In Partnership with Animal Health, Nutrition & Technology USA
June 11-13, 2024 | Boston
animalhealtheventusa.com







INTRODUCTION

At Paws Pharma, we are committed to transforming pet healthcare by prioritizing the wellbeing of pets over profits. Our mission is to support and accelerate the development of innovative treatments that often get overlooked by big pharmaceutical companies due to financial considerations.

By bridging the gap between groundbreaking research and market availability, we strive to bring novel and effective solutions to pets and their owners. In this article we will explore how Paws' efforts align with the FDA approval process for pet medications and how our work is revolutionizing the landscape of pet healthcare.

UNDERSTANDING THE FDA APPROVAL PROCESS FOR PET **MEDICATIONS**

The FDA plays a crucial role in ensuring the safety and efficacy of pet medications. The approval process involves several key stages:

1. DRUG DEVELOPMENT

Drug sponsors develop a new drug compound and seek FDA approval for sale in the United States.

2. PRECLINICAL TESTING

Sponsors must test the new drug on animals to gather basic information on safety and efficacy.

3. INVESTIGATIONAL NEW ANIMAL **DRUG (INAD) APPLICATION**

Submission of data to the FDA to obtain permission to conduct clinical trials.

4. CLINICAL TRIALS

Testing the drug on a larger population of pets to gather more data on safety and efficacy.

5. NEW ANIMAL DRUG APPLICATION

Comprehensive submission to the FDA with all data from research. preclinical testing, and clinical trials.

6. FDA REVIEW AND APPROVAL

The FDA reviews the NADA and decides whether to approve the treatment for market release.



CHALLENGES IN THE CURRENT PET MEDICATION LANDSCAPE

The pet medication landscape is fraught with challenges. Financial and logistical barriers often prevent promising treatments from reaching the market.

Profit-driven motives of big pharmaceutical companies lead to a focus on highly profitable treatments, leaving many effective solutions underfunded and undeveloped. This results in a lack of availability of innovative treatments that could significantly improve pet health.

PAWS' ROLE IN REVOLUTIONIZING PET HEALTHCARE

Paws is dedicated to addressing these challenges by supporting the development of treatments that prioritize pet health over profits. Our role includes:



BRIDGING THE GAP

We connect groundbreaking research with market availability, ensuring that effective treatments do not remain shelved due to financial constraints.



SUPPORTING UNDERSERVED AREAS

We focus on areas of pet health that are often neglected by big pharma, bringing attention and resources to these critical issues.



PROVIDING FUNDING AND RESOURCES

We invest in promising treatments, providing the necessary funding and resources to navigate the complex FDA approval process.



PAWS' EFFORTS IN THE FDA APPROVAL PROCESS



COLLABORATION WITH RESEARCHERS AND VETERINARIANS

We work closely with researchers and veterinarians to identify promising treatments and gather the necessary data for FDA submissions.



FUNDING AND RESOURCES

We provide the financial support needed to conduct preclinical testing, clinical trials, and compile comprehensive NADA submissions.



ADVOCACY

We advocate for more efficient and faster approval processes to ensure that life-saving treatments reach pets in need as quickly as possible.

CASE STUDIES: PAWS' SUCCESS STORIES

One of our notable success stories involves a novel, patented discovery for reducing the overproduction of hyaluronan, a key culprit behind osteoarthritis in pets. Osteoarthritis is a debilitating condition that affects the quality of life for many pets, causing pain and reducing mobility.

Paws Pharma is pursuing the option to license this novel compound, which represents a breakthrough in the treatment of osteoarthritis. Unlike traditional treatments that merely mask symptoms or risk exacerbating the condition, this new treatment targets the root cause by reducing hyaluronan overproduction. This innovation has the potential to significantly improve the quality of lives of pets suffering from osteoarthritis, providing long-term relief and enhanced mobility.



THE IMPORTANCE OF COMMUNITY SUPPORT

Community support is essential for driving change in pet healthcare. Pet owners and advocates play a crucial role in spreading awareness and supporting our mission. By engaging in conversations, sharing our message, and participating in our initiatives, the community helps amplify our efforts and attract the attention of potential investors.

This collective support enables us to continue funding research and development, ensuring that no effective treatment remains undiscovered.

FUTURE DIRECTIONS FOR PAWS AND PET HEALTHCARE

Looking ahead, Paws is committed to expanding our initiatives and setting new standards in pet healthcare. Our future goals include:



LAUNCHING NEW TREATMENTS

Bringing more innovative treatments to market by navigating the FDA approval process efficiently.



EXPANDING RESEARCH

Investing in a broader range of pet health issues to ensure comprehensive care for all pets.



STRENGTHENING COMMUNITY ENGAGEMENT

Building a larger, more active community of pet owners and advocates to support our mission and drive positive change.

CONCLUSION

Paws Pharma is dedicated to transforming pet healthcare by bridging the gap between research and market availability. Our efforts in navigating the FDA approval process, supporting underserved areas, and providing funding and resources are crucial in bringing innovative treatments to pets in need. With the support of our community, we can continue to push boundaries and set new standards in pet health, ensuring that every pet receives the best possible care. Join us in our mission to prioritize pets over profits and make a lasting impact on pet healthcare.